Literature DB >> 26611552

Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.

Eric L Matteson1, Frank Buttgereit2, Christian Dejaco3, Bhaskar Dasgupta4.   

Abstract

Diagnosis of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) is based on typical clinical, histologic, and laboratory features. Ultrasonographic imaging in PMR with assessment especially of subdeltoid bursitis can aid in diagnosis and in following response to treatment. In GCA, diagnosis and disease activity are supported with ultrasonographic, MRI, or [(18)F]fluorodeoxyglucose PET evaluation of large vessels. Glucocorticoids are the primary therapy for PMR and GCA. Methotrexate may be used in patients at high risk for glucocorticoid adverse effects and patients with frequent relapse or needing protracted therapy. Other therapeutic approaches including interleukin 6 antagonists are under evaluation.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Giant cell arteritis; Glucocorticoids; Polymyalgia rheumatica; Treatment

Mesh:

Substances:

Year:  2016        PMID: 26611552     DOI: 10.1016/j.rdc.2015.08.009

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  12 in total

Review 1.  Views on glucocorticoid therapy in rheumatology: the age of convergence.

Authors:  Frank Buttgereit
Journal:  Nat Rev Rheumatol       Date:  2020-02-19       Impact factor: 20.543

2.  Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.

Authors:  Izzat Shbeeb; Divya Challah; Shafay Raheel; Cynthia S Crowson; Eric L Matteson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-02-22       Impact factor: 4.794

3.  Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.

Authors:  Katinka Albrecht; Dörte Huscher; Frank Buttgereit; Martin Aringer; Guido Hoese; Wolfgang Ochs; Katja Thiele; Angela Zink
Journal:  Rheumatol Int       Date:  2017-11-09       Impact factor: 2.631

4.  Increased diagnostic accuracy of giant cell arteritis using three-dimensional fat-saturated contrast-enhanced vessel-wall magnetic resonance imaging at 3 T.

Authors:  Guillaume Poillon; Adrien Collin; Ygal Benhamou; Gaëlle Clavel; Julien Savatovsky; Cécile Pinson; Kevin Zuber; Frédérique Charbonneau; Catherine Vignal; Hervé Picard; Tifenn Leturcq; Sébastien Miranda; Thomas Sené; Emmanuel Gerardin; Augustin Lecler
Journal:  Eur Radiol       Date:  2019-12-06       Impact factor: 5.315

5.  Maximizing patient benefit through a reversed pathway from specialist to generalist: the case of chronic pain.

Authors:  Ioannis Karageorgiou; Stamatios Kokkinakis; Neofytos Maliotis; Christos Lionis; Emmanouil K Symvoulakis
Journal:  Med Pharm Rep       Date:  2021-10-30

Review 6.  Kidney involvement in medium- and large-vessel vasculitis.

Authors:  Federica Maritati; Francesco Iannuzzella; Maria P Pavia; Sonia Pasquali; Augusto Vaglio
Journal:  J Nephrol       Date:  2016-04-20       Impact factor: 3.902

Review 7.  Mechanism and biomarkers in aortitis--a review.

Authors:  Benjamin Benhuri; Ammar ELJack; Bashar Kahaleh; Ritu Chakravarti
Journal:  J Mol Med (Berl)       Date:  2019-10-30       Impact factor: 4.599

8.  Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis.

Authors:  Lana Yin Hui Lai; Emma Harris; Robert M West; Sarah Louise Mackie
Journal:  RMD Open       Date:  2018-02-28

Review 9.  Glucocorticoids-All-Rounders Tackling the Versatile Players of the Immune System.

Authors:  Cindy Strehl; Lisa Ehlers; Timo Gaber; Frank Buttgereit
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

Review 10.  Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.

Authors:  Andriko Palmowski; Frank Buttgereit
Journal:  Curr Rheumatol Rep       Date:  2020-10-12       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.